Latest Conference Articles

Next-generation immunotherapy in breast cancer treatment is an active field of scientific exploration with the potential to yield a vaccine.

Dr. Daniel Osman, the program chair for the Miami Breast Cancer Conference, Discusses the 29th Annual Meeting

Technological advances in genomics have prompted a "sea change" in breast cancer drug development and treatment.

The choice of breast-conserving surgery over mastectomy is often based on fear of recurrence and death rather than clinical evidence.

Pictures from the Annual Miami Breast Cancer Conference, at the Fontainebleau Miami Beach hotel, in Florida.

Debu Tripathy, MD, culled the highlights from abstracts presented in 2011 at the ASCO annual meeting in Chicago, Illinois, and at the CCTR-AARC SABCS in Texas.

The impact of molecular and genomic advancements on the treatment of patients with breast cancer will be among the prime topics of discussion.

As the Miami Breast Cancer Conference enters its 29th year, Osman continues to organize the gathering and pack the 4-day meeting with faculty speakers.

Dr. David Steensma, from Dana-Farber Cancer Institute, Discusses Iron Chelation Therapy for MDS

Certain characteristics of patients with CML can affect therapeutic outcomes.

A number of prognostic factors can help identify those at a high risk for CLL progression who may benefit from early intervention.

Dr. Harry Erba, from the University of Michigan Health System, Describes Proper Diagnostic Testing of CML

Meeting coverage from the 2012 Oncology Nursing Society Congress held at the New Orleans Ernest N. Morial Convention Center, from May 3-6, 2012.

Dr. Kieron Dunleavy from the National Cancer Institute Discusses 3 Molecular Subtypes of DLBCL

A number of studies suggest that there is a right and wrong way to proceed with initial therapy and transplant eligibility for patients with multiple myeloma.

Research has shown that DLBCL is heterogeneous, suggesting that patients with varying subtypes should receive different courses of treatment.

Dr. Stephen Ansell from the Mayo Clinic Describes Waldenström Macroglobulinemia

The treatment of Gaucher disease is poised to enter a new era as a result of advances in the understanding of the cellular pathways at work in the disorder.

Rogerio Vivaldi, MD, has vivid memories of the first patient with Gaucher disease ever treated in Brazil with enzyme replacement therapy.

The mood of the ICHG/ASHG 2011 congress often seemed buoyant as researchers discussed the doors that technology is helping to open.

Dr. Gregory Grabowski, from the University Cincinnati, Explains the Effects of Enzyme Therapy

Pramod K. Mistry, MD, PhD, from Yale University, discusses Gaucher disease

Dr. Anthony Mato From the John Theurer Cancer Center Discusses the Benefits of the JTCC Retrospective Trial

A collection of photos from the ASH 53rd annual meeting at the San Diego Convention Center in San Diego, CA, from December 10-13, 2011.

PACE trial results show patients with previously treated CML achieved a 47% major cytogenetic response rate (MCyR) with ponatinib.

The phase III VISTA trial upholds a persistent and statistically significant survival benefit for bortezomib in previously untreated multiple myeloma patients.

Treatment with GA101 (obinutuzumab) in patients with relapsed non-Hodgkin lymphoma (NHL) resulted in higher response rates compared with rituximab.

Dr. Claudio Anasetti from the H. Lee Moffitt Cancer Center Discusses the Trade-offs of BMT and PBSC

First drug targeting Bruton's tyrosine kinase (Btk) produced high rates of remission in patients with CLL.

Twelve-year results from a Canadian Cancer Society Research Institute study shows chemotherapy alone increases survival in patients with Hodgkin Lymphoma.